Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07780383 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07780383 · ClinicalTrials.gov record · last posted 2026-08-21

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

Name: A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration — clinical trial record (NCT07780383)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorBristol-Myers Squibb

Started2026-08-21

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration

Trial Details

NCT Number	NCT07780383
Lead Sponsor	Bristol-Myers Squibb
Conditions	Alzheimer's Disease, Healthy Participants
Enrollment	84 participants
Start Date	2026-08-21
Primary Completion	2027-06-17 (estimated)
Study Completion	2027-06-17 (estimated)
Updated on ClinicalTrials.gov	2026-08-21